Kevin Yuen, MD
Endocrinology, Diabetes & Metabolism · Phoenix, AZNPI 1528249661
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (52.3%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 23 manufacturers reported payments, led by Novo Nordisk at 37.7% of the total. Among endocrinology, diabetes & metabolism clinicians in AZ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 406 payments — averaging $994.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$152K
- Corcept Therapeutics$57K
- Novo Nordisk Health Care AG$35K
- Neurocrine Biosciences, Inc.$29K
- Recordati_rare_diseases_inc.$26K
- Chiesi USA, Inc.$22K
- plus $83K from 17 others
Across 197 payments — averaging $1767.41 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Ascendis Pharma Endocrinology Inc$123K
- Corcept Therapeutics$97K
- Novo Nordisk AS$40K
- Amryt Pharma Holdings Ltd$35K
- Chiasma, Inc.$24K
- Novartis$11K
- plus $19K from 3 others
What the payments were for
- Consulting fees$211,12852%
- Speaking & faculty fees$121,53530%
- Travel & lodging$62,21615%
- Food & beverage$8,7642%
- Education$1400%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 144 | $152,245 |
| Corcept Therapeutics | 88 | $56,620 |
| Novo Nordisk Health Care AG | 24 | $34,674 |
| Neurocrine Biosciences, Inc. | 32 | $28,999 |
| Recordati_rare_diseases_inc. | 17 | $25,795 |
| Chiesi USA, Inc. | 15 | $21,976 |
| Pfizer(2 entities) | 24 | $19,749 |
| Amryt Pharma Holdings Ltd | 20 | $13,907 |
| Xeris Pharmaceuticals, Inc. | 15 | $13,291 |
| Sandoz | 1 | $11,780 |
| Chiasma, Inc. | 7 | $8,630 |
| Ascendis Pharma Endocrinology Inc | 2 | $8,440 |
| Ipsen Biopharmaceuticals, Inc | 3 | $3,690 |
| Biomarin Pharmaceutical Inc. | 1 | $2,457 |
| Theratechnologies Inc. | 1 | $750 |
| Hexal AG | 1 | $455 |
| AstraZeneca | 1 | $104 |
| EUSA Pharma (US) LLC | 2 | $91 |
| Radius Health, Inc. | 3 | $44 |
| Johnson & Johnson | 2 | $35 |
| Esteve Pharmaceuticals LLC | 1 | $29 |
| Amgen | 1 | $13 |
| Clarus Therapeutics Inc. | 1 | $6 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Norditropin$90,837
- Korlym$55,525
- Macrilen$52,520
- MYCAPSSA$43,941
- Sogroya$31,926
- CRENESSITY$19,870
- ISTURISA$16,969
- RECORLEV$11,220
- SOMAVERT$10,207
- SKYTROFA$8,440
- VYNDAQEL$4,506
- OSILODROSTAT$4,325
- SOMATULINE DEPOT$3,640
- ELIQUIS$2,750
- Palynziq$2,457
- Kuvan$2,457
- GENOTROPIN$2,243
How this compares
$403,782 in reported general payments places this provider in the 95th percentile of 148 endocrinology, diabetes & metabolism providers in Arizona.
See all endocrinology, diabetes & metabolism providers in Arizona →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IsturisaOsilodrostat Phosphate | 81 | $1,150,602 |
| KorlymMifepristone | 20 | $1,089,173 |
| RecorlevLevoketoconazole | 22 | $556,315 |
| SogroyaSomapacitan-Beco | 40 | $169,107 |
| MycapssaOctreotide Acetate | 23 | $145,343 |
| GenotropinSomatropin | 60 | $89,330 |
| Somatuline DepotLanreotide Acetate | 13 | $73,809 |
| OzempicSemaglutide | 36 | $48,428 |
| OmnitropeSomatropin | 21 | $46,662 |
| MounjaroTirzepatide | 24 | $33,762 |
| Testosterone | 49 | $11,169 |
| Hydrocortisone | 120 | $7,082 |
| Desmopressin Acetate | 20 | $4,421 |
| Cabergoline | 29 | $3,420 |
| Levothyroxine Sodium | 150 | $1,776 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Recordati_rare_diseases_inc.Isturisa | $25,795 | $1,150,60281 claims |
| Corcept TherapeuticsKorlym | $56,620 | $1,089,17320 claims |
| Xeris Pharmaceuticals, Inc.Recorlev | $13,291 | $556,31522 claims |
| Novo NordiskSogroya, Ozempic | $152,245 | $217,53476 claims |
| Chiesi USA, Inc.Mycapssa | $21,976 | $145,34323 claims |
| PfizerGenotropin | $19,749 | $89,33060 claims |
| Ipsen Biopharmaceuticals, IncSomatuline Depot | $3,690 | $73,80913 claims |
| Hexal AGOmnitrope | $455 | $46,66221 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 148 endocrinology, diabetes & metabolism providers in Arizona.
Other endocrinology, diabetes & metabolism in Phoenix
- Joan BaileyPhoenix$316K
- Anna BoronPhoenix$32K
- Kari EdlingPhoenix$23K
- James DeerPhoenix$13K
- Lory BarazPhoenix$10K
- Sathya JyothinagaramPhoenix$10K
- Philip LevyPhoenix$9K
- Richard ArakakiPhoenix$6K
- Yasmin AkhunjiPhoenix$5K
- Ahmad Al MaradniPhoenix$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.